MetrioPharm AG
Description
MetrioPharm is a Swiss clinical-stage biotech company that has developed a platform of oral small molecule immune modulators that normalize the pathologically dysregulated (reprogrammed) mitochondrial energy metabolism in macrophages and other immune cells without being immunosuppressive.
MetrioPharm's lead candidate MP1032 normalizes excessive intracellular levels of reactive oxygen species (ROS) back to normal which play an important role in most inflammatory and infectious diseases. MP1032's unique, self-regulating mechanism of action makes it a first-in-class ROS (Reactive Oxygen Species) scavenger that reduces excessive intracellular ROS without (!) interfering with the physiological (normal) ROS levels of other cells, which are essential for cell signaling and other processes.
As a monotherapy, MP1032 produces therapeutic effects similar to corticosteroids - but without serious side effects.
MP1032 in combination with ultra-low dose corticosteroids (reduced by 90% compared to the normal high dose) has the potential to replace the current standard of care of high dose of corticosteroids therapy – with an increased efficacy (2.5 times of the high dose) and significantly reduced side effects.
MP1032 has demonstrated broad-spectrum anti-inflammatory activity in three completed Phase IIa clinical proof-of-concept studies in Psoriasis and COVID-19 involving a total of 234 patients treated with MP1032.
In addition, MP1032 has shown strong efficacy data in preclinical in vivo studies in other inflammatory diseases such as Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Diseases, Sepsis and, most recently, Duchenne Muscular Dystrophy.
MP1032 has also demonstrated a broad host-directed antiviral and antibacterial activity in preclinical and clinical studies, which would be essential for improving future pandemic preparedness.
MetrioPharm has recently raised CHF 18 million in series C financing round and aims for a second closing for further CHF 20m+.
Company members
Thomas Christély, CEO
